WP Advisors LLC Lowers Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

WP Advisors LLC reduced its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,099 shares of the medical research company’s stock after selling 33 shares during the quarter. WP Advisors LLC’s holdings in Thermo Fisher Scientific were worth $572,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the business. Centricity Wealth Management LLC acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at approximately $159,000. Legacy Capital Group California Inc. acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at approximately $988,000. Waterfront Wealth Inc. lifted its holdings in shares of Thermo Fisher Scientific by 53.8% in the 4th quarter. Waterfront Wealth Inc. now owns 2,947 shares of the medical research company’s stock valued at $1,533,000 after buying an additional 1,031 shares during the period. Cromwell Holdings LLC lifted its holdings in shares of Thermo Fisher Scientific by 12.5% in the 4th quarter. Cromwell Holdings LLC now owns 839 shares of the medical research company’s stock valued at $437,000 after buying an additional 93 shares during the period. Finally, ING Groep NV lifted its holdings in shares of Thermo Fisher Scientific by 84.7% in the 4th quarter. ING Groep NV now owns 158,853 shares of the medical research company’s stock valued at $82,640,000 after buying an additional 72,865 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CFO Stephen Williamson sold 9,825 shares of the business’s stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the completion of the sale, the chief financial officer now owns 27,296 shares of the company’s stock, valued at approximately $15,984,264.64. The trade was a 26.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $175,677.00. Following the sale, the executive vice president now directly owns 16,363 shares of the company’s stock, valued at approximately $9,582,009.17. This trade represents a 1.80 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 20,125 shares of company stock valued at $11,231,699. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO opened at $538.03 on Friday. The company has a market cap of $205.80 billion, a P/E ratio of 32.55, a P/E/G ratio of 2.95 and a beta of 0.77. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a 52 week low of $493.30 and a 52 week high of $627.88. The business has a fifty day simple moving average of $548.36 and a 200-day simple moving average of $568.15.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, beating analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific announced that its Board of Directors has authorized a stock buyback program on Friday, November 15th that authorizes the company to repurchase $4.00 billion in shares. This repurchase authorization authorizes the medical research company to buy up to 2% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s board of directors believes its shares are undervalued.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 0.32%. The ex-dividend date is Friday, March 14th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. Thermo Fisher Scientific’s payout ratio is 9.44%.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on TMO shares. Bank of America reduced their price objective on Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating for the company in a report on Friday, December 13th. UBS Group lifted their price objective on Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a “buy” rating in a report on Friday, January 31st. Robert W. Baird reduced their price objective on Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Stifel Nicolaus reduced their price objective on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating for the company in a report on Thursday, October 24th. Finally, Wells Fargo & Company lifted their price objective on Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an “overweight” rating in a report on Friday, January 31st. Four research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $658.00.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.